Medical Device

Entering the UK medical device market is a significant milestone for any biotech or SME company. The pathway to market access can seem complex, but with the right approach, it becomes a manageable and strategic process. I want to share insights that will help you navigate the regulatory landscape confidently, ensuring your innovative medical devices reach patients efficiently and compliantly.

Navigating the UK medical device market can be a complex journey. For biotech and SME companies, understanding the regulatory landscape is crucial to efficiently and safely bringing innovative products to patients. As someone deeply involved in this field, I know that medical device entry consulting is not just about ticking boxes; it’s about creating a strategic pathway that accelerates market access while ensuring compliance and patient safety.

Navigating the complex regulatory compliance landscape in the UK is a critical challenge for biotech and SME companies in the medical device and pharmaceutical sectors. As someone deeply involved in this field, I understand how essential it is to have a trusted partner who can guide you through the intricacies of regulations, ensuring your innovations reach patients safely and efficiently. Regulatory affairs play a pivotal role in this process, acting as the bridge between yo

The EU AI Act (Artificial Intelligence Act Regulation EU 2024/1689), which came into force on 1 August 2024, establishes a harmonised framework for regulating AI systems. It impacts the use of AI in medical settings, particularly when integrated with the EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR).

Navigating the Future of Artificial Intelligence (AI) into Neurotechnology and medical technology (MedTech) is poised to revolutionise healthcare, offering unprecedented diagnostic and therapeutic capabilities.

The convergence of artificial intelligence and pharmaceutical innovation is no longer a distant vision; it’s today’s reality. With a projected market size of $116.49 billion by the end of 2025 and a 27% compound annual growth rate (CAGR), AI in pharma is reshaping everything from drug discovery to diagnostics.

In 2025, manufacturers of AI-powered medical devices face a new regulatory reality. The European Union has introduced the Artificial Intelligence Act (AIA). If your device falls under the Medical Device Regulation (MDR) or the In Vitro Diagnostic Regulation (IVDR), the AIA is mandatory. It’s now a core part of your compliance strategy.

In today's fast-paced world, technology is making remarkable changes across many sectors. Machine learning (ML) frameworks stand out as a...

The rapid growth of machine learning (ML) in recent years has introduced new possibilities in healthcare. These advancements offer the...

The digital health landscape is evolving quickly, thanks to advances in technology like artificial intelligence (AI) and machine learning...